These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 36882218)

  • 1. Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.
    Rodríguez-Carrio J; Burska A; Conaghan PG; Dik WA; Biesen R; Eloranta ML; Cavalli G; Visser M; Boumpas DT; Bertsias G; Wahren-Herlenius M; Rehwinkel J; Frémond ML; Crow MK; Ronnblom L; Vital E; Versnel M
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36882218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.
    Burska A; Rodríguez-Carrio J; Biesen R; Dik WA; Eloranta ML; Cavalli G; Visser M; Boumpas DT; Bertsias G; Wahren-Herlenius M; Rehwinkel J; Frémond ML; Crow MK; Ronnblom L; Conaghan PG; Versnel M; Vital E
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36863752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.
    Rodríguez-Carrio J; Burska A; Conaghan PG; Dik WA; Biesen R; Eloranta ML; Cavalli G; Visser M; Boumpas DT; Bertsias G; Wahren-Herlenius M; Rehwinkel J; Frémond ML; Crow MK; Rönnblom L; Versnel MA; Vital EM
    Ann Rheum Dis; 2023 Jun; 82(6):754-762. PubMed ID: 36858821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
    Drosos GC; Vedder D; Houben E; Boekel L; Atzeni F; Badreh S; Boumpas DT; Brodin N; Bruce IN; González-Gay MÁ; Jacobsen S; Kerekes G; Marchiori F; Mukhtyar C; Ramos-Casals M; Sattar N; Schreiber K; Sciascia S; Svenungsson E; Szekanecz Z; Tausche AK; Tyndall A; van Halm V; Voskuyl A; Macfarlane GJ; Ward MM; Nurmohamed MT; Tektonidou MG
    Ann Rheum Dis; 2022 Jun; 81(6):768-779. PubMed ID: 35110331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.
    Higgs BW; Liu Z; White B; Zhu W; White WI; Morehouse C; Brohawn P; Kiener PA; Richman L; Fiorentino D; Greenberg SA; Jallal B; Yao Y
    Ann Rheum Dis; 2011 Nov; 70(11):2029-36. PubMed ID: 21803750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.
    Gwinnutt JM; Wieczorek M; Cavalli G; Balanescu A; Bischoff-Ferrari HA; Boonen A; de Souza S; de Thurah A; Dorner TE; Moe RH; Putrik P; Rodríguez-Carrio J; Silva-Fernández L; Stamm T; Walker-Bone K; Welling J; Zlatković-Švenda MI; Guillemin F; Verstappen SMM
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35361692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease.
    Tanaka Y; Kusuda M; Yamaguchi Y
    Mod Rheumatol; 2023 Aug; 33(5):857-867. PubMed ID: 36440704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.
    Gwinnutt JM; Wieczorek M; Rodríguez-Carrio J; Balanescu A; Bischoff-Ferrari HA; Boonen A; Cavalli G; de Souza S; de Thurah A; Dorner TE; Moe RH; Putrik P; Silva-Fernández L; Stamm T; Walker-Bone K; Welling J; Zlatković-Švenda M; Guillemin F; Verstappen SMM
    RMD Open; 2022 Jun; 8(2):. PubMed ID: 35654458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.
    Wieczorek M; Gwinnutt JM; Ransay-Colle M; Balanescu A; Bischoff-Ferrari H; Boonen A; Cavalli G; de Souza S; de Thurah A; Dorner TE; Moe RH; Putrik P; Rodríguez-Carrio J; Silva-Fernández L; Stamm TA; Walker-Bone K; Welling J; Zlatkovic-Svenda M; Verstappen SM; Guillemin F
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35351808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of non-pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases.
    Santos EJF; Farisogullari B; Dures E; Geenen R; Machado PM;
    RMD Open; 2023 Aug; 9(3):. PubMed ID: 37604639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures.
    Brohawn PZ; Streicher K; Higgs BW; Morehouse C; Liu H; Illei G; Ranade K
    Lupus; 2019 Nov; 28(13):1524-1533. PubMed ID: 31660791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus.
    Oke V; Gunnarsson I; Dorschner J; Eketjäll S; Zickert A; Niewold TB; Svenungsson E
    Arthritis Res Ther; 2019 Apr; 21(1):107. PubMed ID: 31036046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I Interferons in Autoimmunity: Implications in Clinical Phenotypes and Treatment Response.
    Londe AC; Fernandez-Ruiz R; Julio PR; Appenzeller S; Niewold TB
    J Rheumatol; 2023 Sep; 50(9):1103-1113. PubMed ID: 37399470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B Cell Tetherin: A Flow Cytometric Cell-Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus.
    El-Sherbiny YM; Md Yusof MY; Psarras A; Hensor EMA; Kabba KZ; Dutton K; Mohamed AAA; Elewaut D; McGonagle D; Tooze R; Doody G; Wittmann M; Emery P; Vital EM
    Arthritis Rheumatol; 2020 May; 72(5):769-779. PubMed ID: 31804007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients: a retrospective longitudinal analysis.
    Miyachi K; Iwamoto T; Kojima S; Ida T; Suzuki J; Yamamoto T; Mimura N; Sugiyama T; Tanaka S; Furuta S; Ikeda K; Suzuki K; Niewold TB; Nakajima H
    Arthritis Res Ther; 2023 Feb; 25(1):26. PubMed ID: 36803843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods for type I interferon detection and their relevance for clinical utility and improved understanding of rheumatic diseases.
    Lamot L; Niemietz I; Brown KL
    Clin Exp Rheumatol; 2019; 37(6):1077-1083. PubMed ID: 30943143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.
    Higgs BW; Zhu W; Richman L; Fiorentino DF; Greenberg SA; Jallal B; Yao Y
    Int J Rheum Dis; 2012 Feb; 15(1):25-35. PubMed ID: 22324944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs).
    Mathian A; Felten R; Alarcon-Riquelme ME; Psarras A; Mertz P; Chasset F; Vital EM; Arnaud L
    Joint Bone Spine; 2024 Mar; 91(2):105627. PubMed ID: 37640261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I Interferons in Autoimmunity.
    Fernandez-Ruiz R; Niewold TB
    J Invest Dermatol; 2022 Mar; 142(3 Pt B):793-803. PubMed ID: 35016780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.